Envista (NYSE:NVST) Releases Earnings Results

Envista (NYSE:NVST) announced its earnings results on Thursday. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06, FiscalAI reports. Envista had a net margin of 1.73% and a return on equity of 6.55%. The company had revenue of $750.60 million for the quarter, compared to analyst estimates of $680.26 million. During the same period in the prior year, the business earned $0.24 earnings per share. Envista’s quarterly revenue was up 15.0% on a year-over-year basis. Envista updated its FY 2026 guidance to 1.350-1.450 EPS.

Here are the key takeaways from Envista’s conference call:

• Strong 2025 results and cash returns: Core sales grew 6.5%, adjusted EBITDA rose ~26%, adjusted EPS was $1.19 (up $0.46), free cash flow conversion was 114%, and the company returned over $160 million via share repurchases under a $250 million program.
• 2026 guidance shows continued improvement: Management guides core growth of 2%–4%, adjusted EBITDA growth of 7%–13%, adjusted EPS of $1.35–$1.45, and ~100% free cash flow conversion, with EBITDA and EPS guidance above their medium‑term targets.
• Spark (clear aligners) is now profitable and contributing to margins and growth, with profitable quarters since Q3 and ongoing product and automation investments, though Q4 benefited partly from deferral timing that will unwind.
• Tariffs and FX remain material risks — tariffs cost the company roughly $30M in 2025 and are expected to annualize to about $40M in 2026, while prior transactional FX effects depressed margins and currency uncertainty persists.
• China VBP timing and impact are uncertain — expected ortho and implant VBPs in 2026 could cause quarter-to-quarter order volatility (company models an implant VBP likely in Q2 and ortho in H2), creating execution and timing risk given China is ~7% of sales.

Envista Price Performance

Envista stock opened at $29.17 on Friday. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $4.80 billion, a P/E ratio of 104.18, a PEG ratio of 1.10 and a beta of 1.01. The business has a 50-day moving average of $22.80 and a 200-day moving average of $21.23. Envista has a 1 year low of $14.22 and a 1 year high of $29.28.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Alliancebernstein L.P. boosted its position in shares of Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock worth $119,164,000 after purchasing an additional 1,547,656 shares in the last quarter. Deerfield Management Company L.P. raised its stake in Envista by 3.5% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,294,036 shares of the company’s stock worth $46,730,000 after buying an additional 78,191 shares during the period. Holocene Advisors LP bought a new position in Envista during the second quarter worth about $43,936,000. AQR Capital Management LLC grew its stake in Envista by 7.2% in the second quarter. AQR Capital Management LLC now owns 1,555,211 shares of the company’s stock valued at $30,389,000 after acquiring an additional 104,080 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in Envista in the third quarter valued at about $24,260,000.

More Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 results beat expectations — Envista reported $0.38 EPS vs. $0.32 consensus and revenue of $750.6M versus ~ $680M est., with revenue up ~15% year-over-year. Strong results are the primary driver of the move higher. Envista Reports Fourth Quarter 2025 Results
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $1.35–$1.45 vs. consensus ~ $1.27 — the stronger outlook (and beat + guidance combo) is supportive of the rally and suggests better-than-expected near-term growth. Press Release / Slide Deck
• Neutral Sentiment: Earnings materials and call transcripts are available for deeper read — the conference call transcript and slide deck provide management commentary on drivers (product mix, geographic trends, margins) that investors should review to judge sustainability. Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Wall‑street writeups and snapshots (Zacks, Yahoo, Investing) highlight the beat and value/Growth characteristics — useful for screening but not new catalysts by themselves. Zacks Q4 Metrics
• Negative Sentiment: Analyst targets still imply downside — JPMorgan and Wells Fargo both raised targets to $26 but kept neutral/equal‑weight ratings; those $26 targets sit below the current market level, which could cap upside or prompt caution once headline momentum fades. Benzinga – JPMorgan Benzinga – Wells Fargo

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVST. Evercore restated an “outperform” rating and issued a $32.00 price objective on shares of Envista in a research report on Friday. William Blair raised Envista from a “hold” rating to an “outperform” rating in a research note on Friday. Robert W. Baird set a $30.00 target price on Envista in a research report on Friday. UBS Group upped their price target on Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Evercore ISI set a $32.00 price objective on Envista and gave the stock an “outperform” rating in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $26.50.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.